9th Annual Comprehensive Hematology and Oncology Review Course 2018
OVERVIEW
9th Annual Comprehensive Hematology and Oncology Review Course is organized by Seattle Cancer Care Alliance (SCCA) and will be held from Sep 15 - 18, 2018 at Motif Seattle, Seattle, Washington, United States of America.
The target audience for this medical event is physicians and allied health professionals with a hematology/oncology focus who desire a review and update in current standards of care for patients. The course will be helpful to those preparing for certification or re-certification. This CME Conference has been approved for a maximum of 34.00 AMA PRA Category 1 Credits.
Course Description :
This four-day program will cover data supporting guidelines, recommendations and recent advances regarding therapeutic options for patients with solid tumors and hematologic disorders. At the end of the course, physicians will leave with a comprehensive syllabus, self-assessment and deeper understanding of the pathogenesis, diagnostic evaluation and therapeutic modalities available for a breadth of solid tumors and hematologic disorders. There will be a case-based review session and discussion. The course is designed to help prepare you for certifying and/or recertifying exams.
Conference Objectives are:-
Upon completion of this activity, attendees should be able to:
• Describe the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common malignant hematological diseases.
• Describe the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common solid tumor malignancies.
• Integrate guideline-based treatments into clinical practice while personalizing care appropriately for the patient.
• Integrate new therapeutic and diagnostic approaches into clinical practice as appropriate.
The target audience for this medical event is physicians and allied health professionals with a hematology/oncology focus who desire a review and update in current standards of care for patients. The course will be helpful to those preparing for certification or re-certification. This CME Conference has been approved for a maximum of 34.00 AMA PRA Category 1 Credits.
Course Description :
This four-day program will cover data supporting guidelines, recommendations and recent advances regarding therapeutic options for patients with solid tumors and hematologic disorders. At the end of the course, physicians will leave with a comprehensive syllabus, self-assessment and deeper understanding of the pathogenesis, diagnostic evaluation and therapeutic modalities available for a breadth of solid tumors and hematologic disorders. There will be a case-based review session and discussion. The course is designed to help prepare you for certifying and/or recertifying exams.
Conference Objectives are:-
Upon completion of this activity, attendees should be able to:
• Describe the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common malignant hematological diseases.
• Describe the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common solid tumor malignancies.
• Integrate guideline-based treatments into clinical practice while personalizing care appropriately for the patient.
• Integrate new therapeutic and diagnostic approaches into clinical practice as appropriate.
KEY DATES
15 Sep, 2018
Event Start Date
18 Sep, 2018
Event End Date
SPECIALITIES
HaematologyOncologySUGGESTED HOTELS
CONFERENCE VENUE
Motif Seattle
Quick Links